MoneyDiscourse
← All companies

ABBV

AbbVie Inc. · Health Care

8 quarters · 75 figures · latest Q3 FY2026 filed 2026-10-30 →

Compared

6 of 8 · select any line below to add or remove it ·

  • Net revenues

    $17.4bn+10.3% Y/Y

    Q3 FY2026

  • Net earnings

    $4.22bn+2144.7% Y/Y

    Q3 FY2026

  • Diluted earnings per share attributable to AbbVie Inc.

    $2.37+2270.0% Y/Y

    Q3 FY2026

  • Gross margin ratio

    75.4%

    Q3 FY2026

  • Operating earnings

    $6.27bn+229.1% Y/Y

    Q3 FY2026

  • Acquired IPR&D and milestones

    $216m−91.9% Y/Y

    Q3 FY2026

Reported figures

Click any line for its full history. Each figure links to the filing it was read from.

Income statement

24 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Acquired IPR&D and milestonesacquired_iprd_milestones
$1.27bn$744m$291m$216m−91.9%−25.8%
Cost of products soldcost_of_products_sold
$4.55bn$4.22bn$4.29bn$4.29bn−19.2%−0.1%
As adjusted (non-GAAP) cost of products soldcost_of_products_sold_non_gaap
$2.73bn$2.46bn$2.6bn$2.6bn+2.1%+0.1%
Diluted earnings per share attributable to AbbVie Inc.eps_diluted
$1.02$0.39$2.03$2.37+2270.0%+16.7%
Adjusted diluted earnings per shareeps_diluted_non_gaap
$2.71$2.65$3.65$3.82+105.4%+4.7%
Income tax expenseincome_tax_expense
$853m$342m$662m$609m+15.8%−8.0%
Interest expense, netinterest_expense_net
$655m$645m$679m$700m+4.9%+3.1%
Net earningsnet_income
$1.82bn$697m$3.62bn$4.22bn+2144.7%+16.7%
As adjusted (non-GAAP) after-tax earningsnet_income_non_gaap
$4.83bn$4.71bn$6.49bn$6.8bn+105.5%+4.7%
Operating earningsoperating_income
$4.54bn$3.99bn$6.43bn$6.27bn+229.1%−2.6%
Earnings before income tax expensepretax_income
$2.67bn$1.04bn$4.28bn$4.83bn+576.3%+12.9%
As adjusted (non-GAAP) pre-tax earningspretax_income_non_gaap
$5.91bn$5.57bn$7.61bn$7.87bn+79.6%+3.3%
Research and developmentrd_expense
$2.58bn$2.47bn$2.34bn$2.57bn+10.7%+9.5%
As adjusted (non-GAAP) R&Drd_expense_non_gaap
$2.56bn$2.27bn$2.31bn$2.43bn+7.5%+4.8%
Selling, general and administrativesga_expense
$3.9bn$3.58bn$3.63bn$4.09bn+14.5%+12.5%
As adjusted (non-GAAP) SG&Asga_expense_non_gaap
$3.71bn$3.4bn$3.57bn$3.69bn+8.1%+3.2%
Weighted-average diluted shares outstandingdiluted_shares
—1,7741,7711,772+0.0%+0.1%
Net earnings attributable to AbbVie Inc.net_income_attributable
—$695m$3.61bn$4.22bn+2167.7%+16.7%
Other expense, netother_expense_net
—$2.31bn$1.48bn$738m+41.1%−50.0%
Total operating costs and expensestotal_operating_costs
—$11.01bn$10.56bn$11.14bn−19.7%+5.5%
Net revenuestotal_revenue
—$15bn$16.99bn$17.4bn+10.3%+2.4%
As adjusted (non-GAAP) income taxesincome_tax_expense_non_gaap
—$856m——+17.9%—
Net revenuesnet_revenue
$16.62bn———+10.0%—
Adjusted net interest expenseinterest_expense_net_non_gaap————$688m——

Segments

34 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Aestheticsaesthetics_revenue
$1.29bn$1,186bn$1,282bn$1,176bn—−8.3%
Botox Cosmeticbotox_cosmetic_revenue
$717m$668m$728m$669m—−8.1%
Botox Therapeuticbotox_therapeutic_revenue
$990m$1.01bn$1.04bn$1.08bn—+3.6%
Creoncreon_revenue
$385m$361m$345m$361m—+4.6%
Elahereelahere_revenue
$182m$198m$211m$224m—+6.2%
Epkinlyepkinly_revenue
$81m$83m$103m$108m—+4.9%
Humirahumira_revenue
$1.25bn$688bn$756bn$683bn—−9.7%
Imbruvicaimbruvica_revenue
$671m$556m$532m$522m—−1.9%
Immunologyimmunology_revenue
$8.63bn$7,290bn$8,786bn$9,165bn—+4.3%
Juvederm Collectionjuvederm_revenue
$249m$232m$245m$222m—−9.4%
Mavyretmavyret_revenue
$324m$351m$295m$265m—−10.2%
Neuroscienceneuroscience_revenue
$2.96bn$2,875bn$3,228bn$3,389bn—+5.0%
Oncologyoncology_revenue
$1.66bn$1,631bn$1,650bn$1,696bn—+2.8%
Other Aestheticsother_aesthetics_revenue
$320m$286m$309m$285m—−7.8%
Other Key Productsother_key_products_revenue
$884m$995m$935m$965m—+3.2%
Quliptaqulipta_revenue
$288m$296m$350m$398m—+13.7%
Rinvoqrinvoq_revenue
$2.37bn$2,119bn$2,525bn$2,706bn—+7.2%
Skyriziskyrizi_revenue
$5.01bn$4,483bn$5,505bn$5,776bn—+4.9%
Ubrelvyubrelvy_revenue
$339m$339m$392m$449m—+14.5%
Venclextavenclexta_revenue
$710m$770m$771m$803m—+4.2%
Vraylarvraylar_revenue
$1.02bn$905bn$1,071bn$1,068bn—−0.3%
Vyalevvyalev_revenue
$183m$201m$256m$286m—+11.7%
Linzesslinzess_revenue
—$283m$295m$339m—+14.9%
Other Neuroscienceother_neuroscience_revenue
—$125m$117m$108m—−7.7%
Other Oncologyother_oncology_revenue
—$24m$33m$39m—+18.2%
Net revenues Int'l.net_revenues_international
—$4.03bn—$4.07bn——
Net revenues U.S.net_revenues_us
—$10.97bn—$13.33bn——
Duodopaduodopa_revenue—$92m—————
Eye Careeye_care_revenue—$580m—————
Int'l. net revenuesinternational_net_revenue—$3.82bn—————
Linzess/Constellalinzess_constella_revenue—$175m—————
Net revenues Int'l.revenue_international———$4.13bn———
Net revenues U.S.revenue_us———$12.86bn———
U.S. net revenuesus_net_revenue—$12.79bn—————

Operating

1 line

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Unfavorable impact of acquired IPR&D and milestones expense per shareiprd_milestones_eps_impact
$0.71———−19.3%—

Margins

16 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Tax ratetax_rate
32.0%32.9%15.5%12.6%−82.9%−18.7%
Adjusted tax ratetax_rate_non_gaap
18.3%15.4%14.7%13.6%−44.5%−7.5%
Gross margin ratiogross_margin
72.6%71.9%74.7%75.4%—+0.9%
Adjusted gross margin ratiogross_margin_non_gaap
83.6%83.6%84.7%85.1%—+0.5%
Operating margin ratiooperating_margin
27.3%26.6%37.9%36.0%—−5.0%
Adjusted operating margin ratiooperating_margin_non_gaap
38.3%40.8%48.3%48.7%—+0.8%
Acquired IPR&D and milestones expense as percent of net revenuesacquired_iprd_percent_of_revenue
7.6%5.0%—1.2%——
R&D expense as percent of net revenuesrd_percent_of_revenue
15.5%16.5%—14.7%——
Adjusted R&D expense as percent of net revenuesrd_percent_of_revenue_non_gaap
15.4%15.1%—13.9%——
SG&A expense as percent of net revenuessga_percent_of_revenue
23.4%23.9%—23.5%——
Adjusted SG&A expense as percent of net revenuessga_percent_of_revenue_non_gaap
22.3%22.7%—21.2%——
Acquired IPR&D and milestones expense as percent of net revenuesacquired_iprd_pct_revenue———1.7%———
R&D expense as percent of net revenuesrd_pct_revenue———13.8%———
Adjusted R&D expense as percent of net revenuesrd_pct_revenue_non_gaap———13.6%———
SG&A expense as percent of net revenuessga_pct_revenue———21.4%———
Adjusted SG&A expense as percent of net revenuessga_pct_revenue_non_gaap———21.0%———

Guided vs delivered

What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.

Data from company filings. Not investment advice.